FLT3 and acute myeloid leukemia: Given the broad array of resistance mechanisms to FLT3 inhibition, as well as the polyclonal nature of FLT3-mutated AML, one of the most promising current strategies is to combine FLT3 inhibitors with other antileukemic agents (Tables 1, 2).